Eli Lilly (LLY) Acquisitions (2010 - 2022)

Eli Lilly (LLY) has 11 years of Acquisitions data on file, last reported at $327.2 million in Q4 2022.

• For the quarter ending Q4 2022, Acquisitions changed N/A year-over-year to $327.2 million; the trailing twelve-month figure through Dec 2022 stood at $327.2 million (down 56.22% YoY), and the FY2022 full-year result was $327.2 million, down 56.22% from the prior year.
• Acquisitions for Q4 2022 stood at $327.2 million, down from $747.4 million in the prior quarter.
• Across five years, Acquisitions topped out at $6.9 billion in Q1 2019 and bottomed at $327.2 million in Q4 2022.
• The 4-year median for Acquisitions is $798.3 million (2020), against an average of $2.2 billion.
• The widest annual swing landed in 2020, when Acquisitions tumbled 87.72%; it then slipped 12.0% in 2021.
• A 4-year view of Acquisitions shows it stood at $6.9 billion in 2019, then sank by 87.72% to $849.3 million in 2020, then slipped by 12.0% to $747.4 million in 2021, then tumbled by 56.22% to $327.2 million in 2022.
• The last three Acquisitions figures came in at $327.2 million (Q4 2022), $747.4 million (Q1 2021), and $849.3 million (Q1 2020), per Business Quant data.

Peer Comparison